blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2975942

EP2975942 - TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.06.2019
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  06.07.2018
FormerGrant of patent is intended
Status updated on  26.03.2018
FormerExamination is in progress
Status updated on  31.03.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Sangamo Therapeutics, Inc.
501 Canal Blvd.
Suite A100
Richmond, CA 94804 / US
For all designated states
Ospedale San Raffaele S.r.l.
Via Olgettina 60
20132 Milano / IT
[2017/41]
Former [2016/04]For all designated states
Sangamo BioSciences, Inc.
Suite A100, 501 Canal Boulevard
Richmond, CA 94804 / US
For all designated states
Ospedale San Raffaele S.r.l.
Via Olgettina 60
20132 Milano / IT
Inventor(s)01 / GREGORY, Philip D.
c/o SANGAMO BIOSCIENCES INC.
501 Canal Blvd.
Suite A100
Richmond, California 94804 / US
02 / HOLMES, Michael C.
c/o SANGAMO BIOSCIENCES INC.
501 Canal Blvd.
Suite A100
Richmond, California 94804 / US
03 / PASCHON, David
c/o SANGAMO BIOSCIENCES INC.
501 Canal Blvd.
Suite A100
Richmond, California 94804 / US
04 / ZHANG, Lei
c/o SANGAMO BIOSCIENCES INC.
501 Canal Blvd.
Suite A100
Richmond, California 94804 / US
05 / BONINI, Maria Chiara
c/o OSPEDALE SAN RAFFAELE SRL
Via Olgettina 60
I-20132 Milan / IT
06 / GENOVESE, Pietro
c/o OSPEDALE SAN RAFFAELE SRL
Via Olgettina 60
I-20132 Milan / IT
07 / MAGNANI, Zulma
c/o OSPEDALE SAN RAFFAELE SRL
Via Olgettina 60
I-20132 Milan / IT
08 / MASTAGLIO, Sara
c/o OSPEDALE SAN RAFFAELE SRL
Via Olgettina 60
I-20132 Milan / IT
09 / NALDINI, Luigi
c/o OSPEDALE SAN RAFFAELE SRL
Via Olgettina 60
I-20132 Milan / IT
 [2016/04]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2016/04]Brasnett, Adrian Hugh
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date14770870.520.03.2014
[2016/04]
WO2014US31360
Priority number, dateUS201361804076P21.03.2013         Original published format: US 201361804076 P
[2016/04]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014153470
Date:25.09.2014
Language:EN
[2014/39]
Type: A2 Application without search report 
No.:EP2975942
Date:27.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 25.09.2014 takes the place of the publication of the European patent application.
[2016/04]
Type: B1 Patent specification 
No.:EP2975942
Date:08.08.2018
Language:EN
[2018/32]
Search report(s)International search report - published on:US04.12.2014
(Supplementary) European search report - dispatched on:EP11.10.2016
ClassificationIPC:A01N63/00, C12N9/16, C12N15/00, C07H21/04
[2016/04]
CPC:
A61K35/26 (EP,IL,US); A61K39/0011 (US); A61K39/001188 (US);
A61K39/4611 (EP,IL); A61K39/4632 (EP,IL); A61K39/464453 (EP,IL);
A61K39/464488 (EP,IL); A61P31/00 (EP,IL); A61P35/00 (EP,IL);
A61P37/06 (EP,IL); C12N15/86 (EP,IL,US); C12N15/87 (EP,IL,US);
C12N15/907 (EP,IL,US); A61K2039/5156 (US); A61K2039/5158 (US);
A61K2239/38 (EP,IL); A61K2239/48 (EP,IL); C12N2501/515 (EP,IL,US);
C12N2510/00 (EP,IL,US); C12N2740/16043 (EP,IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/04]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:GEZIELTE DISRUPTION VON T-ZELL REZEPTORGENEN MIT MANIPULIERTEN ZINKFINGER-PROTEINNUKLEASEN[2016/04]
English:TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES[2016/04]
French:INTERRUPTION CIBLÉE DE GÈNES DE RÉCEPTEUR DES LYMPHOCYTES T À L'AIDE DE NUCLÉASES PROTÉIQUES À DOIGT DE ZINC GÉNÉTIQUEMENT MODIFIÉES[2016/04]
Entry into regional phase06.10.2015National basic fee paid 
06.10.2015Search fee paid 
06.10.2015Designation fee(s) paid 
06.10.2015Examination fee paid 
Examination procedure06.10.2015Examination requested  [2016/04]
16.02.2017Amendment by applicant (claims and/or description)
30.03.2017Despatch of a communication from the examining division (Time limit: M04)
17.07.2017Reply to a communication from the examining division
21.09.2017Despatch of a communication from the examining division (Time limit: M04)
29.01.2018Reply to a communication from the examining division
27.03.2018Communication of intention to grant the patent
27.06.2018Fee for grant paid
27.06.2018Fee for publishing/printing paid
27.06.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.03.2017
Opposition(s)09.05.2019No opposition filed within time limit [2019/29]
Fees paidRenewal fee
10.03.2016Renewal fee patent year 03
10.03.2017Renewal fee patent year 04
13.03.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.03.2014
AL08.08.2018
AT08.08.2018
CY08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
MK08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
TR08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
IE20.03.2019
LU20.03.2019
MT20.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
[2022/31]
Former [2021/32]HU20.03.2014
AL08.08.2018
AT08.08.2018
CY08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
TR08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
IE20.03.2019
LU20.03.2019
MT20.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2021/26]AL08.08.2018
AT08.08.2018
CY08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
TR08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
IE20.03.2019
LU20.03.2019
MT20.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/29]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
TR08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
IE20.03.2019
LU20.03.2019
MT20.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/16]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
TR08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
IE20.03.2019
LU20.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/11]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
IE20.03.2019
LU20.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/09]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
IE20.03.2019
LU20.03.2019
Former [2020/01]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
LU20.03.2019
Former [2019/46]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/37]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
SM08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/26]AL08.08.2018
AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SK08.08.2018
SM08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/23]AL08.08.2018
AT08.08.2018
CZ08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
SK08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/22]AL08.08.2018
AT08.08.2018
CZ08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
RS08.08.2018
SE08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/12]AL08.08.2018
AT08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RS08.08.2018
SE08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/11]AT08.08.2018
FI08.08.2018
HR08.08.2018
LT08.08.2018
NL08.08.2018
PL08.08.2018
RS08.08.2018
SE08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/10]AT08.08.2018
FI08.08.2018
LT08.08.2018
NL08.08.2018
PL08.08.2018
RS08.08.2018
SE08.08.2018
BG08.11.2018
NO08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/09]FI08.08.2018
LT08.08.2018
NL08.08.2018
NO08.11.2018
IS08.12.2018
Former [2019/08]FI08.08.2018
LT08.08.2018
NO08.11.2018
IS08.12.2018
Former [2019/07]LT08.08.2018
Documents cited:Search[XI]US2011158957  (BONINI MARIA CHIARA [IT], et al) [X] 1-7,9-15 * figure 3; example 7 * [I] 8;
 [X]  - ELENA PROVASI ET AL, "Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer", NATURE MEDICINE, (20120401), vol. 18, no. 5, doi:10.1038/nm.2700, ISSN 1078-8956, pages 807 - 815, XP055181611 [X] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1038/nm.2700
 [X]  - H. TORIKAI ET AL, "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, (20120614), vol. 119, no. 24, doi:10.1182/blood-2012-01-405365, ISSN 0006-4971, pages 5697 - 5705, XP055071623 [X] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1182/blood-2012-01-405365
 [A]  - ZHAO YANGBING ET AL, "Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tunior cell lines", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20050401), vol. 174, no. 7, doi:10.4049/JIMMUNOL.174.7.4415, ISSN 0022-1767, pages 4415 - 4423, XP002669894 [A] 8

DOI:   http://dx.doi.org/10.4049/jimmunol.174.7.4415
International search[Y]US2011158957  (BONINI MARIA CHIARA [IT], et al);
 [Y]WO2012138939  (DUCHATEAU PHILIPPE [FR], et al)
ExaminationWO2012012667
 WO2013074916
    - "Human TRAC gene target site, SEQ ID 128.", Geneseq, (20120315), Database accession no. AZS87188, URL: EBI
    - "Human TRAC gene target site, SEQ ID 129.", Geneseq, (20120315), Database accession no. AZS87189, URL: EBI
    - "Human TRBC gene target site, SEQ ID 130.", Geneseq, (20120315), Database accession no. AZS87190, URL: EBI
    - "Human TRBC gene target site, SEQ ID 131.", Geneseq, (20120315), Database accession no. AZS87191, URL: EBI
by applicant   - ROBBINS ET AL., J CLIN ONCOL, (2011), vol. 29, no. 7, pages 917 - 924
    - KANEKO ET AL., BLOOD, (2009), vol. 113, no. 5, page 1006
    - BONDANZA ET AL., BLOOD, (2011), vol. 117, no. 24, page 6469
    - AMENDOLA ET AL., NAT. BIOTECHNOL, (2005), vol. 23, pages 108 - 116
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.